Authors
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLCSteven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.
Latest:
Dr. Horwitz on Ongoing Trials in T-Cell LymphomaSteven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.
Latest:
Dr. Park on Alisertib in Myc-Overexpressing Lymphoma CellsSteven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.
Latest:
Dr. Sherman Defines RAI Resistance in Thyroid CancerSteven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.
Latest:
Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNSSteven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
Latest:
Payers Manipulate Definition of NecessityWhen it comes to health coverage, most Americans face an unnerving reality—they have no idea what is covered under their health insurance policy until they are affected by illness or disease.
Latest:
How Genetic Testing Impacts Breast Cancer Treatment DecisionsAs genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions.
Latest:
Dr. Katz on Precision Medicine in Breast CancerSteven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.
Latest:
Dr. Grunberg on Barriers to Effective Supportive CareSteven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.
Latest:
Dr. Horwitz Discusses the Results of the ECHELON-2 StudySteven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).
Latest:
Dr. Lipkin on Cancer Prevention Vaccine in Preclinical Model of Lynch SyndromeSteven M. Lipkin, MD, PhD, the Gladys and Roland Harriman Professor of Medicine, professor of medicine in the Division of Gastroenterology and Hepatology, and vice chair for research in the Weill Department of Medicine at Weill Cornell Medicine; and a geneticist at NewYork-Presbyterian/Weill Cornell Medical Center, discusses a study of a cancer prevention vaccine in a preclinical model of Lynch syndrome during the 2019 AACR Annual Meeting
Latest:
Dr. Alberts on Unmet Needs in CRCSteven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).
Latest:
Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic MalignanciesSteven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.
Latest:
Dr. Treon on Breakthroughs in Waldenström's MacroglobulinemiaSteven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.
Latest:
Chasing the Holy Grail of EHR InteroperabilityCOTA Inc, an independent health care informatics company was founded to build research-grade, real-world data to exponentially improve outcomes and reduce costs—ensuring the right care for the right patient every time.
Latest:
Dr. Goldberg on Financial Toxicities Faced in HematologyStuart L. Goldberg, MD, discusses financial toxicities faced in hematology.
Latest:
Dr. Lutzker on OX40 Agonist in Patients With Refractory Solid TumorsStuart Lutzker, MD, PhD, vice president of BioOncology Exploratory Clinical Development, Genentech, discusses results of the first-in-human study of OX40 agonist in patients with refractory solid tumors.
Latest:
Dr. Lichtman Discusses Supportive and Palliative CareDr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.
Latest:
Dr. Mukherjee on Radioactive Iodine Treatment of Thyroid Cancer and Risk of MDSSudipto Mukherjee, MD, associate staff, Department of Hematology and Oncology, Cleveland Clinic, discusses a study examining the association between radioactive iodine treatment of thyroid cancer and the risk for developing myelodysplastic syndromes.
Latest:
Dr. Movva on Molecular Profiling in SarcomaSujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.
Latest:
Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal CancerSujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).
Latest:
Autophagy Modulation May Be a Novel Approach to Treatment of Advanced CancersAlthough prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.
